CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 192 enrolled
Drug / intervention
bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01241240
NCT01241240Phase 3Completed
CompareCT.gov

Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Allergan·interventional·Posted Nov 16, 2010·Updated Sep 10, 2014

In Brief

A Phase 3 clinical trial evaluating bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy) and Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 192 participants across 2 sites in 2 countries.

Detailed Summary

This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesColombia, Mexico
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 16, 2010
Enrollment StartMar 1, 2011
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 15.6 years ago

Interventions

bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)drug

One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.

Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solutiondrug

One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.